Bel Marra Nutritionals supports recent clinical study that will assess heart drug treatments on elderly patients
Bel Marra Health, well known for offering high-quality, specially formulated vitamins and nutritional supplements, has commented on a recent study that will assess heart drug treatments on elderly patients
In a current clinical study published recently in the journal Trials, the effects of each specific drug treatment for heart failure will be monitored in patients 80 years old and older. This clinical trial started in October 2011 and will continue on until December 2012. The main goal of the clinical trial was to determine the actual effect of drug treatment schemes for elderly patients.
The proponents of the study explained that although ACE inhibitors and beta-blockers are the most common drugs administered to heart failure patients, the clinical performed on these drugs involved younger patients, within the age range of 61 to 71.
The clinical trial involves approximately 80 heart failure patients that are at least 80 years old. The study participants were randomly classified into two study groups, one group being given the classic treatment, which is the administration of at least one cardiovascular drug, whereas the other group will be subjected to an optimized treatment consisting of prescription drugs and regular day-hospital monitoring.
The two study groups will then be assessed at the end of the study period for various indicators, including their quality of life, mortality, readmission for heart failure, breathing capacity, and development of other cardiovascular symptoms or events.
The study participants will also be examined for specific physical features, including walking capacity and breathing volume. Spokesperson for Bel Marra Health Dr Victor Marchione commented in the clinical study saying, "The elderly are usually afflicted with difficulty in breathing and thus those with cardiovascular problems find breathing much more difficult to perform".
The study participants will be asked to walk for approximately six minutes, during which they will be monitored in terms of heart rate and breathing. The number of breathing cycles at each minute will be monitored, in relation to the number of heart beats per minute. This walking test will also provide the investigators in determining whether the capacity and quality for breathing differs in each study group.
CEO of Bel Marra Health Jim Chiang says, "It would be interesting to know if each treatment is as effective as what the earlier clinical trial described, when younger patients were examined. If the results show similar outcomes, then this clinical trial will serve as a validation of the general treatment regimen for heart failure patients."
By the end of 2012, the results of this clinical trial will be complete and the actual benefits of drug treatment of above-80 year old patients will be determined.
(SOURCE: "American Heart Journal", Incidence, clinical predictors, and prognostic impact of worsening renal function in elderly patients with chronic heart failure on intensive medical therapy January, 2012)
Bel Marra Health, as the distributor of Extra Strength Omega-3 Miracle which contains the optimal dose of omega-3, offers high-quality vitamins and nutritional supplements in formulations designed to address specific health concerns. All ingredients are backed with scientific evidence. Every product is tested for safety, quality, and purity at every stage of the manufacturing process. Furthermore, Bel Marra Health products are produced only in Health Canada approved facilities, going that extra mile to ensure our health conscious customers are getting top quality products. For more information on Bel Marra Nutritionals visit http://www.belmarrahealth.com or call 1-866-531-0466
###
Categories: Health
Press Release Options
Visit Web Site
Printer FriendlyAbout This Press Release
If you have any questions about this press release, please contact the listed publisher. Please do not contact prHWY as we cannot help you with your inquiry.